Education
About Us
Working with TipRanks
Follow Us
Bone Therapeutics S.A. (DE:BT1)
FRANKFURT:BT1
Total Valuation
Bone Therapeutics has a market cap or net worth of €1.24M. The enterprise value is ―.
Market Cap€1.24M
Enterprise Value―
Share Statistics
Bone Therapeutics has 652,862,300 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding652,862,300
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Bone Therapeutics’s return on equity (ROE) is 1.26 and return on invested capital (ROIC) is -127.14%.
Return on Equity (ROE)1.26
Return on Assets (ROA)-3.01
Return on Invested Capital (ROIC)-127.14%
Return on Capital Employed (ROCE)1.12
Revenue Per Employee45.25K
Profits Per Employee-2.40M
Employee Count12
Asset Turnover0.06
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Bone Therapeutics is -0.29. Bone Therapeutics’s PEG ratio is >-0.01.
PE Ratio-0.29
PS Ratio0.00
PB Ratio-0.02
Price to Fair Value-0.37
Price to FCF-0.54
Price to Operating Cash Flow-0.13
PEG Ratio>-0.01
Income Statement
In the last 12 months, Bone Therapeutics had revenue of 543.00K and earned -28.78M in profits. Earnings per share was -0.21.
Revenue543.00K
Gross Profit543.00K
Operating Income-7.04M
Pretax Income-29.03M
Net Income-28.78M
EBITDA-6.80M
Earnings Per Share (EPS)-0.21
Cash Flow
In the last 12 months, operating cash flow was -2.37M and capital expenditures 12.00K, giving a free cash flow of -1.95M billion.
Operating Cash Flow-2.37M
Free Cash Flow-1.95M
Free Cash Flow per Share>-0.01
Dividends & Yields
Bone Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta-3.20
52-Week Price Change20.00%
50-Day Moving Average0.01
200-Day Moving Average―
Relative Strength Index (RSI)48.89
Average Volume (3m)0.00
Important Dates
Bone Therapeutics upcoming earnings date is Apr 24, 2025, TBA Not Confirmed.
Last Earnings DateOct 28, 2024
Next Earnings DateApr 24, 2025
Ex-Dividend Date―
Financial Position
Bone Therapeutics as a current ratio of 0.12, with Debt / Equity ratio of -130.93%
Current Ratio0.12
Quick Ratio0.12
Debt to Market Cap3.27
Net Debt to EBITDA-4.13
Interest Coverage Ratio-1.18
Taxes
In the past 12 months, Bone Therapeutics has paid -7.00K in taxes.
Income Tax-7.00K
Effective Tax Rate<0.01
Enterprise Valuation
Bone Therapeutics EV to EBITDA ratio is -5.36, with an EV/FCF ratio of -10.50.
EV to Sales67.09
EV to EBITDA-5.36
EV to Free Cash Flow-10.50
EV to Operating Cash Flow-10.50
Balance Sheet
Bone Therapeutics has €816.00K in cash and marketable securities with €26.79M in debt, giving a net cash position of €25.98M billion.
Cash & Marketable Securities€816.00K
Total Debt€26.79M
Net Cash€25.98M
Net Cash Per Share€0.04
Tangible Book Value Per Share-€0.19
Margins
Gross margin is 90.74%, with operating margin of -1296.50%, and net profit margin of -5299.82%.
Gross Margin90.74%
Operating Margin-1296.50%
Pretax Margin-5345.86%
Net Profit Margin-5299.82%
EBITDA Margin-1251.57%
EBIT Margin-1296.32%
Analyst Forecast
The average price target for Bone Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―